Skip to main content
Robert Baiocchi, MD, Hematology, Columbus, OH

RobertAlanBaiocchiMDPhD

Hematology Columbus, OH

Hematologic Oncology

Professor, Internal Medicine, Ohio State University College of Medicine

Dr. Baiocchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Baiocchi's full profile

Already have an account?

  • Office

    460 W 10th Ave
    5th Floor
    Columbus, OH 43210
    Phone+1 614-293-3196
    Fax+1 614-293-4812

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 1999 - 2001
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1999
  • SUNY BUffalo
    SUNY BUffaloMD, medicine, 1995 - 1997
  • State University of New York College
    State University of New York CollegePh.D, Physiology, 1994
  • State University of New York College
    State University of New York CollegeM.S., Natural Science, 1993
  • State University of New York College
    State University of New York CollegeB.S., Biology, 1989

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2000 - 2025

Awards, Honors, & Recognition

  • Early Career Innovator of the Year Nomination The Ohio State University, 2012
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Innovation Award-Semi Finalist Inventor of the Year Nomination Tech Columbus, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo  
    Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Exp Hematol, 1/1/2015
  • AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma  
    Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
  • The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...  
    Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Targeting Hypersumoylation in Mantle Cell Lymphoma
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Post graduate career options for the physician scientist 
    Chicago, IL - 1/26/2015
  • Targeting Histone Methyltransferases and Demethylases track 
    Boston, MA - 1/24/2015
  • Join now to see all

Other

  • It’s All About Health 
    Baiocchi RA, Show Joy 106.3
    1/5/2011
  • OSU James Care East Expansion 
    Baiocchi RA, Show Joy 106.3
    1/5/2011

Press Mentions

  • OSU Doctor Looks into Viruses That May Lead to Cancer
    OSU Doctor Looks into Viruses That May Lead to CancerMay 11th, 2019
  • Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
    Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
  • Possible New Target for Future Brain Cancer Drugs
    Possible New Target for Future Brain Cancer DrugsFebruary 27th, 2014
  • Join now to see all

Grant Support

  • Development Of Novel Compounds To Inhibit PRMT5 Enzyme In High Grade AstrocytomasNational Institute Of Neurological Disorders And Stroke2010–2011
  • Development Of Vaccine Strategies To Prevent EBV+ Lymphoma In Patients With HIVNational Cancer Institute2009–2010
  • Ptld: Cytokine Production And Gene PolymorphismsNational Cancer Institute2005
  • Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2003